Actuate Therapeutics (NASDAQ: ACTU) is a clinical-stage oncology company focused on the discovery and development of targeted therapies designed to address key drivers of tumor growth and survival. Headquartered in South San Francisco, California, the company applies a precision medicine approach to identify novel molecular targets and develop small-molecule agents that have the potential to improve outcomes for patients with difficult-to-treat cancers.
The company’s lead asset, atuveciclib, is a selective, oral CDK9 inhibitor being evaluated in a Phase 1 clinical trial for patients with acute myeloid leukemia and advanced solid tumors. By inhibiting CDK9, atuveciclib is designed to disrupt transcription-dependent survival pathways in malignant cells. In addition to its CDK9 program, Actuate is advancing preclinical research on a tumor-homing peptide–drug conjugate that aims to selectively deliver cytotoxic payloads to integrin-expressing tumor cells, thereby enhancing therapeutic index and minimizing off-target effects.
Since its founding in 2018, Actuate has built its research and development operations in the San Francisco Bay Area, leveraging collaborations with leading academic institutions and contract research organizations. The company’s clinical trials are currently conducted at premier oncology centers across the United States, with plans to expand its geographic footprint into Europe and Asia as its pipeline advances through development milestones.
Actuate’s leadership team comprises industry veterans with extensive experience in oncology research, translational science and biopharmaceutical commercialization. By combining deep scientific expertise with a streamlined development strategy, the company aims to rapidly advance its targeted therapies toward clinical proof of concept and ultimately to regulatory approval.
AI Generated. May Contain Errors.
